In the Hong Kong stock IPO market, there were no new offerings, 2 new shares passed the hearing and 3 new shares were submitted this week. In terms of fund-raising, as of December 12, 2021, 88 new shares (excluding one REITs) were listed in Hong Kong this year, raising a total of HK $313.628 billion.
What is worth paying attention to this week is that the intrusive cardiovascular device company Prozac and the domestic "small nucleic acid drug first unit" San Nuo Pharmaceuticals have been heard by the Hong Kong Stock Exchange; Bowei Smart Technology, which ranks first in the market for IT solutions in Macau, has submitted its form to the Hong Kong Stock Exchange.
1 IPO period
There are no new shares to apply for this week, you can pay attention to the latest listing process of the company that has passed the hearing and submitted the form.
2 through the hearing
Two new shares have passed the hearing this week, namely:
1) Shanghai Baixin'an Biotechnology Co., Ltd., from Shanghai, is China's leading innovative invasive cardiovascular device company, currently focusing on the following two treatments: (I) fully degradable stent (BRS) therapy and (ii) renal nerve occlusion (RDN) therapy. As of the latest practicable date, it has one core product, Bioheart ®, and eight other pipeline products under development at different development stages. As the company has no commercialized products at present, nor does it generate any revenue from product sales. During the track record period, Propranolol did not make a profit and incurred operating losses. From 2019 to June 30, 2021, its annual losses were 23.72 million yuan, 340 million yuan and 228 million yuan respectively.
2) Sirnaomics Ltd. (referred to as "San Nuo Pharmaceuticals"), from Suzhou City, Jiangsu Province, is an international biopharmaceutical company specializing in the research, development and industrialization of innovative drugs for RNAi and mRNA, and the first pharmaceutical company in the world to achieve positive IIa clinical results in the field of oncology with RNAi therapy. In terms of performance, Nuo Pharmaceuticals has not yet generated any revenue from product sales, with only other revenues of $440000 and $771000, respectively, from 2019 to 2020. The annual losses during the period were $17.127 million and $46.428 million, respectively.
3 the latest delivery form
This week, three new shares have been submitted to the HKEx, namely:
1) Yibo Financial Holdings LimitedFrom Hong Kong, China, is a financial services provider providing a wide range of financial and wealth management services. From 2018 to 2020, its realized income was HK $107 million, HK $122 million and HK $142 million, respectively.
2) Bowei Wisdom Technology Co., Ltd.From Macau, China, is a supplier of reliable, end-to-end and high-quality enterprise IT solutions to customers. In terms of revenue in 2020, it ranks first in the market for IT solutions in Macau, with a market share of 25.2%. From 2018 to 2020, the company's realized income was HK $354 million, HK $503 million and HK $475 million, respectively.
3) Rico healthy living Co., Ltd.From Shenzhen City, Guangdong Province, is an integrated property management service provider, the service network covers the Yangtze River Delta, Great Bay area, Bohai Rim and Central China and other strategic core areas. As of June 30, 2021, it has a total of 88 projects under management, with a total construction area of 13.9 million square meters and a total contract construction area of 22 million square meters. From 2018 to 2020, the company's realized income was 124 million yuan, 181 million yuan and 222 million yuan respectively.